

Validation data for Anti-CoV-N-hIgG1 (clone CR3018)

<https://www.invivogen.com/sars2-nucleocapsid-cr3018-mab>

For research use only

Version 20L02-ED

Anti-CoV-N-hIgG1 is a recombinant monoclonal antibody (mAb) featuring the variable region of the SARS-CoV/SARS-CoV-2 nucleocapsid mAb (clone CR3018), which specifically targets the nucleocapsid protein, and the constant region of the human IgG1 (hIgG1) isotype. The binding of the antibody has been validated by ELISA using a coated SARS-CoV-2 nucleocapsid-His fusion protein (Figure 1).

Binding of Anti-CoV-N-hIgG1 to SARS-CoV-2 nucleocapsid by ELISA




Figure 1: Validation of binding to SARS-CoV-2 nucleocapsid by ELISA. SARS-CoV-2 nucleocapsid-His fusion protein (5 µg/ml) was coated onto ELISA plates overnight. A serial dilution of Anti-CoV-N-hIgG1 (red curve) or Anti-β-Gal-hIgG1 (control antibody; grey curve) was added to the pre-coated plate and incubated for 1 hour. Subsequently, binding was detected with a HRP-labelled anti-hIgG1 antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride). Absorbance was read at 490 nm.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3-622-34-80

E-mail: info@invivogen.com